TY - JOUR
T1 - 2nd ESMO consensus conference on lung cancer
T2 - Early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up
AU - Vansteenkiste, J.
AU - Crinò, L.
AU - Dooms, C.
AU - Douillard, J. Y.
AU - Faivre-Finn, C.
AU - Lim, E.
AU - Rocco, G.
AU - Senan, S.
AU - van Schil, P.
AU - Veronesi, G.
AU - Stahel, R.
AU - Peters, S.
AU - Felip, E.
AU - Kerr, Keith
AU - Besse, Benjamin
AU - Eberhardt, Wilfried
AU - Edelman, Martin
AU - Mok, Tony
AU - O'Byrne, Ken
AU - Novello, Silvia
AU - Bubendorf, Lukas
AU - Marchetti, Antonio
AU - Baas, Paul
AU - Reck, Martin
AU - Syrigos, Konstantinos
AU - Paz-Ares, Luis
AU - Smit, Egbert F.
AU - Meldgaard, Peter
AU - Adjei, Alex
AU - Nicolson, Marianne
AU - Weder, Walter
AU - de Ruysscher, Dirk
AU - Le Pechoux, Cecile
AU - de Leyn, Paul
AU - Westeel, Virginie
N1 - © The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].
PY - 2014/8
Y1 - 2014/8
N2 - To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines in advanced disease, earlystage disease and locally advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on early-stage disease.
AB - To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines in advanced disease, earlystage disease and locally advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on early-stage disease.
KW - Carcinoma, Non-Small-Cell Lung/diagnosis
KW - Consensus
KW - Cytodiagnosis/statistics & numerical data
KW - Early Detection of Cancer
KW - Humans
KW - Lung Neoplasms/diagnosis
KW - Monitoring, Physiologic/methods
KW - Neoplasm Staging/methods
KW - Pneumonectomy/methods
KW - Radiosurgery/statistics & numerical data
KW - Risk Assessment
KW - Tomography, X-Ray Computed/statistics & numerical data
UR - http://www.scopus.com/inward/record.url?scp=84904545741&partnerID=8YFLogxK
U2 - 10.1093/annonc/mdu089
DO - 10.1093/annonc/mdu089
M3 - Article
C2 - 24562446
AN - SCOPUS:84904545741
SN - 0923-7534
VL - 25
SP - 1462
EP - 1474
JO - Annals of Oncology
JF - Annals of Oncology
IS - 8
ER -